Sign up to save your podcasts
Or
Share Gamma Secretase Inhibition et al
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Gamma Secretase Inhibition et al
The recent approval of nirogacestat, the first gamma secretase inhibitor on the market, provides a great opportunity to discuss desmoid tumors and Notch signaling.
Review article: https://doi.org/10.1002/onco.13627
Also, a new T-cell malignancy warning for most CAR-T products. And, is belantamab mafodotin coming back based on the DREAMM-7 results?
View all episodes
By John Bossaer
4.9
185185 ratings
The recent approval of nirogacestat, the first gamma secretase inhibitor on the market, provides a great opportunity to discuss desmoid tumors and Notch signaling.
Review article: https://doi.org/10.1002/onco.13627
Also, a new T-cell malignancy warning for most CAR-T products. And, is belantamab mafodotin coming back based on the DREAMM-7 results?
More shows like OncoPharm
View all
JAMA Clinical Reviews
502 Listeners
The Daily
113,207 Listeners
Up First from NPR
57,056 Listeners
Armchair Expert with Dax Shepard
69,753 Listeners
ASCO Guidelines
46 Listeners
The Peter Attia Drive
8,718 Listeners
OncLive® On Air
22 Listeners
Raising Good Humans
1,898 Listeners
Oncology Today with Dr Neil Love
58 Listeners
Huberman Lab
29,391 Listeners
The Money with Katie Show
1,561 Listeners
Two Onc Docs
195 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
46 Listeners
WolverHeme Happy Hour
30 Listeners
Good Hang with Amy Poehler
13,496 Listeners